On October 22, 2015, David Lowe resigned as a memb
Post# of 30067
Posted On: 10/28/2015 9:04:55 PM
On October 22, 2015, David Lowe resigned as a member of the Board of Directors of the Company, effective immediately, for personal reasons and after terminating the consulting agreement dated November 1, 2014 by and between the Company and NeuroAssets Sarl. Dr. Lowe is President and CEO of NeuroAssets Sarl.
Personal reasons could me a lot of things:
- Got another gig lined up with his consulting company
- 69 and want to retire or try something different
- 12 month contract ended now. Dr. Lowe had to make a decision to commit to another 12 months or move on.
- Took a bullet for the team to preserve cash since Elto on hold
- Move to balance the dependent/independent director requirement
- The company has Dr. Curtis Scribner now to focus on accelerating worldwide regulatory pathways
- Quit so he could buy the company outright
- All of the above
- Some of the above
- None of the above
Salary: $207,000/yr
Bonus: $60,000 upon uplist
Part-time: 60%
Age: 69
Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery - JANUARY 14, 2014
Quote:
"The in-license of Eltoprazine represents a major corporate milestone for Amarantus, moving the therapeutic pipeline from purely a pre-clinical pipeline with MANF, to a balanced pipeline with both clinical and pre-clinical assets," said David A. Lowe, PhD, member of the Amarantus Board of Directors. "The 5HT1a/1b pathway is emerging as a key biological pathway in the LID-space, and Eltoprazine is the most advanced drug candidate in this class. Adequately addressing LID in Parkinson's disease would represent a significant improvement to the standard of care for patients worldwide and is a significant commercial opportunity."
http://www.amarantus.com/news/press-releases/...esia-phase
Amarantus Appoints David A. Lowe, PhD to Board of Directors - NOVEMBER 06, 2013
We continue to believe that Parkinson's disease (PD) is a very attractive therapeutic application for MANF given the data produced to date. However, orphan indications such as Retinitis Pigmentosa present a tremendous opportunity to speed the time to market for MANF, thereby increasing its net present value at the same time as facilitating success in PD and other indications that have more complicated regulatory pathways . I am very excited with the opportunity to take on a formal role with Amarantus at this time as the Company has made significant corporate progress over the last year and is poised for significant growth as we move forward."
http://ir.amarantus.com/press-releases/detail...-directors
President & CEO of NeuroAssets
http://www.neuroassets.com/
Consulting Agreement
http://ir.amarantus.com/all-sec-filings/conte...070503.pdf
Personal reasons could me a lot of things:
- Got another gig lined up with his consulting company
- 69 and want to retire or try something different
- 12 month contract ended now. Dr. Lowe had to make a decision to commit to another 12 months or move on.
- Took a bullet for the team to preserve cash since Elto on hold
- Move to balance the dependent/independent director requirement
- The company has Dr. Curtis Scribner now to focus on accelerating worldwide regulatory pathways
- Quit so he could buy the company outright
- All of the above
- Some of the above
- None of the above
Salary: $207,000/yr
Bonus: $60,000 upon uplist
Part-time: 60%
Age: 69
Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery - JANUARY 14, 2014
Quote:
"The in-license of Eltoprazine represents a major corporate milestone for Amarantus, moving the therapeutic pipeline from purely a pre-clinical pipeline with MANF, to a balanced pipeline with both clinical and pre-clinical assets," said David A. Lowe, PhD, member of the Amarantus Board of Directors. "The 5HT1a/1b pathway is emerging as a key biological pathway in the LID-space, and Eltoprazine is the most advanced drug candidate in this class. Adequately addressing LID in Parkinson's disease would represent a significant improvement to the standard of care for patients worldwide and is a significant commercial opportunity."
http://www.amarantus.com/news/press-releases/...esia-phase
Amarantus Appoints David A. Lowe, PhD to Board of Directors - NOVEMBER 06, 2013
We continue to believe that Parkinson's disease (PD) is a very attractive therapeutic application for MANF given the data produced to date. However, orphan indications such as Retinitis Pigmentosa present a tremendous opportunity to speed the time to market for MANF, thereby increasing its net present value at the same time as facilitating success in PD and other indications that have more complicated regulatory pathways . I am very excited with the opportunity to take on a formal role with Amarantus at this time as the Company has made significant corporate progress over the last year and is poised for significant growth as we move forward."
http://ir.amarantus.com/press-releases/detail...-directors
President & CEO of NeuroAssets
http://www.neuroassets.com/
Consulting Agreement
http://ir.amarantus.com/all-sec-filings/conte...070503.pdf
(0)
(0)